Saxenda (Liraglutide) for Weight Loss: FDA Label, SCALE Trial Evidence, and the New Teva Generic (2026)

Saxenda (liraglutide 3 mg, Novo Nordisk) is the original injectable GLP-1 receptor agonist FDA-approved for chronic weight management — first approved December 23, 2014, expanded to adolescents 12-17 in December 2020. The pivotal SCALE Obesity and Prediabetes phase 3 trial (Pi-Sunyer NEJM 2015, PMID 26132939) reported a primary endpoint of -8.0% mean body-weight change at 56 weeks on liraglutide 3 mg vs -2.6% on placebo. The watershed news for 2026: on August 28, 2025, Teva Pharmaceuticals received FDA approval for generic liraglutide 3 mg referencing Saxenda — the first FDA-approved generic GLP-1 receptor agonist for chronic weight management in the United States. Saxenda's ~8% body-weight effect size is meaningfully smaller than Wegovy (~14.9% at 68 weeks, STEP-1) and Zepbound (~20.9% at 72 weeks, SURMOUNT-1), and the daily-vs -weekly injection cadence is a real adherence trade-off. Below: the verbatim FDA label, the SCALE trial evidence, the Teva generic, the Aetna 1227-C 4% continuation rule, and the patient profiles for whom Saxenda still makes sense.

What is Saxenda?

Saxenda is liraglutide 3 mg in a multi-dose prefilled pen for once-daily subcutaneous injection. It is sponsored by Novo Nordisk Inc. (NDA 206321, DailyMed SetID 3946d389-0926-4f77-a708-0acb8153b143).

• Active ingredient: liraglutide — a glucagon-like peptide-1 (GLP-1) receptor agonist with 97% amino-acid homology to native human GLP-1
• Route: subcutaneous injection (abdomen, thigh, or upper arm)
• Schedule: once daily, any time of day, with or without food
• Maintenance dose: 3.0 mg once daily
• FDA approval (adults): December 23, 2014 for chronic weight management
• FDA approval (adolescents 12-17): December 4, 2020 — one of the few FDA-approved anti-obesity medications with an adolescent indication
• NOT the same as Victoza: Victoza is also liraglutide but is dosed at 1.2 or 1.8 mg daily and is FDA-approved for type 2 diabetes only (not weight management). Same molecule, different dose, different indication, different brand, different label.

FDA-approved indication (verbatim from §1)

Per the Saxenda DailyMed label §1 INDICATIONS AND USAGE:

“SAXENDA is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in:
• Adult patients with an initial body mass index (BMI) of:
    º 30 kg/m² or greater (obesity), or
    º 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).
• Pediatric patients aged 12 years and older with:
    º body weight above 60 kg, and
    º an initial BMI corresponding to 30 kg/m² or greater for adults (obesity) by international cut-offs.”

The pediatric expansion (December 2020) makes Saxenda one of the few FDA-approved anti-obesity medications with an adolescent indication — alongside Wegovy (FDA-approved for adolescents 12+ in December 2022), Qsymia (12+, 2022 expansion), and Zepbound (the WAVE-1 adolescent program is ongoing as of 2026).

Saxenda dosing schedule (verbatim from §2)

Per the DailyMed label §2 DOSAGE AND ADMINISTRATION, Saxenda is dose-escalated over five steps, with each step lasting at least 1 week, until the maintenance 3.0 mg dose is reached:

Verbatim from §2: “If patients do not tolerate an increased dose during dose escalation, consider delaying dose escalation for approximately one additional week. Discontinue SAXENDA if patients cannot tolerate the 3 mg dose.”

Stop rule (also §2 verbatim): “Evaluate the change in body weight 16 weeks after initiating SAXENDA. Discontinue SAXENDA if a patient has not lost at least 4% of baseline body weight, since it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment.” (This 4% label-stop threshold is also why Aetna uses a 4% continuation rule for Saxenda specifically — see below.)

SCALE Obesity and Prediabetes — the canonical phase 3 evidence

SCALE Obesity and Prediabetes (Pi-Sunyer et al., NEJM 2015, PMID 26132939) is the canonical phase 3 trial that anchored the Saxenda FDA approval. From the published paper:

• Design: 56-week, randomized, double-blind, placebo-controlled, multicenter phase 3 trial. n=3,731 adults with BMI ≥30 (obesity) OR BMI ≥27 with dyslipidemia or hypertension. All patients had non-diabetic baseline glycemia (33% had prediabetes).
• Arms (2:1 randomization): liraglutide 3.0 mg subcutaneous daily (n=2,487) vs placebo (n=1,244). Both arms received a -500 kcal/day diet plus 150 min/week exercise lifestyle intervention.
• Primary endpoint — mean percent body-weight change at 56 weeks:
  • Liraglutide 3.0 mg: -8.0% (-8.4 kg)
  • Placebo: -2.6% (-2.8 kg)
  • Difference: -5.4 percentage points (p<0.001)
• Categorical responder analysis at 56 weeks:
  • ≥5% baseline weight loss: 63.2% on liraglutide vs 27.1% on placebo
  • ≥10% baseline weight loss: 33.1% on liraglutide vs 10.6% on placebo
• Secondary endpoints: reductions in waist circumference, blood pressure, fasting glucose, and lipid profile in the liraglutide arm. Among patients with baseline prediabetes, prediabetes regressed in 69.2% on liraglutide vs 32.7% on placebo at 56 weeks.

SCALE Diabetes — T2D + obesity replication

SCALE Diabetes (Davies et al., JAMA 2015, PMID 26284720) replicated the SCALE Obesity finding in a separate population: adults with type 2 diabetes plus obesity or overweight with comorbidity.

• Design: 56-week, randomized, double- blind, placebo-controlled phase 3 trial. n=846 adults with BMI ≥27, T2D managed with diet alone or with oral antidiabetic agents, and HbA1c 7.0-10.0%.
• Arms: liraglutide 3.0 mg, liraglutide 1.8 mg (the diabetes Victoza dose), or placebo, all once daily.
• Primary endpoint — mean percent body-weight change at 56 weeks:
  • Liraglutide 3.0 mg: -6.0%
  • Liraglutide 1.8 mg: -4.7%
  • Placebo: -2.0%
• The T2D effect size is smaller than the non-T2D population in SCALE Obesity (-6.0% vs -8.0%) on the same 3.0 mg dose. The general principle — GLP-1 weight loss is larger in non-T2D populations than T2D populations — was first systematically documented here and has since been confirmed across the STEP-1 vs STEP-2 (semaglutide) and SURMOUNT-1 vs SURMOUNT-2 (tirzepatide) phase 3 programs.

SCALE Maintenance — weight maintenance after diet induction

SCALE Maintenance (Wadden et al., Int J Obes 2013, PMID 23812094) tested liraglutide for weight maintenance after an initial low-calorie-diet-induced weight loss:

• Design: 56-week, randomized, double- blind, placebo-controlled phase 3 trial. n=422 adults with BMI ≥30 (or ≥27 with comorbidities) who had first lost ≥5% body weight on a low-calorie diet run-in.
• Arms: liraglutide 3.0 mg vs placebo, both with continued lifestyle intervention.
• Result: patients on liraglutide lost an additional -6.2% body weight from randomization vs -0.2% on placebo, AND maintained a larger total weight loss from the original pre-run-in baseline.

Saxenda for adolescents (12-17) — December 2020 expansion

FDA approved Saxenda for pediatric patients aged 12 and older on December 4, 2020, based on a randomized, placebo-controlled phase 3 trial of liraglutide 3 mg in adolescents with obesity (Kelly et al., NEJM 2020). The pediatric §2 dosing follows the same 0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg five-step weekly escalation as adults, but the dose at which the patient remains is the maximum tolerated dose up to 3.0 mg (rather than mandating 3.0 mg).

This makes Saxenda one of the few FDA-approved anti- obesity medications with an adolescent indication. For the comparable adolescent indications and head-to-head considerations across this cluster, see our Wegovy vs Mounjaro decision guide.

Saxenda side effects (verbatim from §6)

Per the DailyMed §6 ADVERSE REACTIONS section, the most common adverse reactions (≥5% on Saxenda + >placebo) across the SCALE clinical trial program were:

• Nausea — ~39% on Saxenda vs ~14% on placebo. Most common reason for early discontinuation; typically dose-related and worst during early titration.
• Hypoglycemia — among T2D patients (SCALE Diabetes population), more frequent on Saxenda plus a sulfonylurea than placebo plus a sulfonylurea
• Diarrhea — ~21% on Saxenda vs ~10% placebo
• Constipation — ~19% on Saxenda vs ~9% placebo
• Vomiting — ~16% on Saxenda vs ~4% placebo
• Headache — ~14% on Saxenda vs ~12% placebo (modest signal)
• Decreased appetite — ~10%
• Dyspepsia — ~10%
• Fatigue — ~8%
• Dizziness — ~7%
• Abdominal pain — ~7%
• Increased lipase — lab abnormality present in a meaningful subset of patients; warrants attention because of the pancreatitis warning (see below)

Boxed warning and contraindications

Saxenda carries the GLP-1 class boxed warning verbatim from the label:

“WARNING: RISK OF THYROID C-CELL TUMORS — Liraglutide causes thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether SAXENDA causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined. SAXENDA is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).”

Verbatim §4 contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Prior serious hypersensitivity reaction to liraglutide or any of the product's components
• Pregnancy — the §8.1 Pregnancy section instructs that Saxenda be discontinued at least 2 months before a planned pregnancy due to the long washout time of liraglutide and that women receiving Saxenda are advised to use effective contraception

Other §5 warnings include acute pancreatitis, acute gallbladder disease, hypoglycemia in T2D patients on sulfonylureas/insulin, heart-rate increase, renal impairment, hypersensitivity reactions, and a §5 suicidal behavior and ideation safety surveillance disclosure that was removed from the label in early 2026 following the FDA Drug Safety Communication of January 13, 2026 (no causal signal found in pooled 91 placebo- controlled trials, n=107,910). For the broader Drug Safety Communication context see our GLP-1 mental health evidence article.

Why Saxenda has been increasingly displaced by Wegovy + Zepbound

Saxenda's ~8% mean body-weight loss at 56 weeks (SCALE Obesity) is meaningfully smaller than the once-weekly GLP-1s approved more recently. Cross-trial indirect comparison — not head-to-head — with the canonical phase 3 publications:

Caveats on cross-trial comparison: SCALE, STEP-1, and SURMOUNT-1 enrolled different patient populations (BMI distribution, prediabetes prevalence, baseline weight), ran for different durations (56 vs 68 vs 72 weeks), used different lifestyle-intervention intensities, and used different statistical handling of treatment discontinuation. The numbers above are not head-to-head; they are the published primary endpoints from each pivotal trial. The only direct head-to-head between two of these drugs in patients with obesity without diabetes is SURMOUNT-5 (NEJM 2025, PMID 40353578), which compared tirzepatide vs semaglutide directly — liraglutide was not in the comparison.

Why effect-size matters less than it sounds in some patient profiles:

• Patients who only need ~5-10% weight loss for a comorbid condition (NAFLD, sleep apnea, insulin resistance, prediabetes regression) plausibly hit their goal on Saxenda. The SCALE Obesity trial reported 63% of liraglutide patients achieved ≥5% baseline weight loss — a clinically meaningful threshold.
• Daily-vs-weekly cadence is a real adherence variable in both directions. Weekly is generally easier (fewer injections), but some patients actually prefer daily because there is no big “am I overdue” gap, the daily ritual becomes habit, and missed doses are smaller hits to plasma exposure.
• Saxenda has 11 years of US post-marketing surveillance. Wegovy has 4 years; Zepbound has ~2.5 years. Patients prioritizing real-world long-term safety experience may favor liraglutide.
• Wegovy and Zepbound are not available to everyone. Supply, formulary, and PA-rejection patterns still constrain access. For patients blocked from those two, Saxenda is a real alternative.

The Teva generic liraglutide 3 mg approval (August 28, 2025)

On August 28, 2025, the FDA approved Teva Pharmaceuticals' generic liraglutide injection 3 mg (referencing Saxenda). This is the first FDA-approved generic GLP-1 receptor agonist for chronic weight management in the United States.

Two earlier generic GLP-1s were FDA-approved before the Teva Saxenda generic, but neither was for weight management:

• Hikma generic liraglutide referencing Victoza — FDA-approved December 2024, FOR TYPE 2 DIABETES (Victoza's indication), not for weight management
• Amneal generic exenatide referencing Byetta — FDA-approved November 21, 2024, FOR TYPE 2 DIABETES. AstraZeneca discontinued the Byetta brand in October 2024, so the practical retail impact is limited.

For the full landscape of generic GLP-1 timing, including when generic Wegovy/Ozempic semaglutide and generic Mounjaro/Zepbound tirzepatide are realistically expected, see our When will each GLP-1 go generic? deep dive.

What “generic Saxenda” actually means at the pharmacy

• Hatch-Waxman ANDA pathway. Liraglutide is a peptide drug, but it has historically been regulated under the small-molecule Hatch-Waxman pathway (NDA / ANDA) rather than the biologic BLA / 351(k) biosimilar pathway, because of its synthetic-peptide manufacturing route and its original NDA filing. Teva submitted an Abbreviated New Drug Application (ANDA) referencing brand Saxenda's NDA 206321.
• AB-rated bioequivalent. Per the FDA Orange Book therapeutic-equivalence framework, the Teva generic liraglutide 3 mg is rated AB — therapeutically equivalent and bioequivalent to brand Saxenda. Patients can expect the same clinical effect.
• Pharmacist-substitutable subject to state pharmacy law. Most US states permit pharmacist-initiated generic substitution for AB-rated generics unless the prescriber writes “dispense as written” (DAW) or the patient declines substitution. Saxenda generic substitution follows the same rules.
• Same boxed warning, same indication, same dosing, same contraindications. Generic liraglutide 3 mg references the brand Saxenda label; therefore the §1 indication, §2 dosing, §4 contraindications, §5 warnings, §6 adverse reactions, and boxed warning are the same.
• Pricing is still settling out. Generic GLP-1 launches don't produce the dramatic 80-95% price drops seen in oral small-molecule generics because injectable peptide manufacturing is more capital-intensive. Early generic-liraglutide pricing has been modestly below brand Saxenda but well above $99-149 oral-pill levels seen in the GLP-1 space.

Insurance coverage and the Aetna 1227-C 4% continuation rule

Saxenda is on most commercial weight-management formularies, but coverage criteria differ from Wegovy and Zepbound. The most important detail patients consistently misread is Aetna's unique 4% (NOT 5%) baseline-weight-loss continuation threshold for Saxenda.

Aetna publishes a distinct PA bulletin for Saxenda (1227-C P08-2024_R, dated 12/19/2024). Verbatim from the bulletin:

• Adult eligibility: “BMI of 30 kg/m² or greater (obese), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition” — comorbidity list: “hypertension, type 2 diabetes mellitus, or dyslipidemia” (NOTE: this list is shorter than Wegovy 4774-C's 11-condition list)
• Pediatric eligibility (12-17): BMI “corresponding to 30 kg/m² or greater for adults by international cut-offs (Cole Criteria)” plus a 6-month documented weight-management program
• Adult continuation (verbatim): “lost at least 4 percent of baseline body weight OR…maintain their initial 4 percent weight loss.”
• Pediatric continuation: “at least 1 percent reduction in BMI from baseline.”
• Medicare GLP-1 Bridge: Saxenda is NOT included in the Aetna Medicare GLP-1 Bridge. MA-PD members who want a covered weight- loss GLP-1 path under the bridge have to switch to Wegovy, Zepbound KwikPen, or Foundayo.

The 4% continuation rule traces directly to the Saxenda FDA label §2 stop rule: “Discontinue SAXENDA if a patient has not lost at least 4% of baseline body weight [at 16 weeks].” Aetna applies the label number verbatim. Wegovy and Zepbound use a 5% continuation rule because the corresponding §2 stop rules in those labels use 5% (consistent with the larger effect sizes those drugs achieve in trials). The patient takeaway: do not assume Saxenda needs 5% continuation — the correct Aetna threshold is 4%.

For the verbatim verbiage and the eight other Aetna bulletins covering Wegovy, Zepbound, Mounjaro, Ozempic, and Foundayo, plus the CVS Caremark July 2025 formulary swap context (the dominant 2026 denial driver), see our Aetna GLP-1 prior authorization guide.

When Saxenda makes sense in 2026

Patient profiles for whom Saxenda (or generic liraglutide 3 mg) is a reasonable first choice over Wegovy or Zepbound:

• Patients blocked from Wegovy or Zepbound on their formulary (PA denied, exclusion list, supply interruption) but where Saxenda is covered — this is the most common Saxenda-favoring scenario in 2026
• Patients who prefer a daily ritual over a weekly one, who want finer dose-titration granularity, or who get larger plasma-exposure swings on weekly dosing
• Patients already on Saxenda and meeting their weight-loss goal — a successful maintenance regimen does not need to be switched to a higher-effect-size drug just because the higher-effect- size drug exists
• Adolescents 12-17 — Saxenda is one of the few FDA-approved AOMs with an adolescent indication; family/clinician preference may favor starting with the longer-evidence drug
• Patients prioritizing the lowest acquisition cost — the Teva generic enables a modestly lower cash-pay channel than brand Saxenda for patients without weight-management formulary coverage, though cash-pay remains expensive relative to oral options
• Patients who previously had unacceptable side effects on once-weekly semaglutide or tirzepatide and who tolerate the smoother- plasma-curve daily liraglutide profile
• Patients preferring the longer real-world safety surveillance record (11 years for Saxenda vs 4 years for Wegovy and ~2.5 years for Zepbound)

Who should NOT take Saxenda?

• Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 (verbatim contraindication; class effect for all GLP-1 RAs)
• Pregnancy or planning pregnancy within 2 months — Saxenda is contraindicated in pregnancy and the label instructs discontinuation at least 2 months before a planned pregnancy
• Prior serious hypersensitivity to liraglutide or any product component
• Patients prioritizing the largest possible weight loss — Zepbound (~20.9%) and Wegovy (~14.9%) outperform Saxenda (~8.0%) in cross-trial comparison, and patients who need higher effect size for their goal should probably go directly to one of those drugs
• Patients unwilling to commit to once-daily injection — Wegovy and Zepbound are weekly, Foundayo is a daily oral pill, and Qsymia / Contrave / generic phentermine are oral options

Bottom line

• Saxenda (liraglutide 3 mg) was the original injectable GLP-1 receptor agonist FDA-approved for chronic weight management. December 23, 2014 in adults; December 4, 2020 expanded to adolescents 12+.
• SCALE Obesity (PMID 26132939) reported -8.0% mean body-weight change at 56 weeks vs -2.6% placebo, n=3,731. 63.2% of liraglutide patients lost ≥5% of baseline body weight. SCALE Diabetes (PMID 26284720) replicated in T2D + obesity at -6.0%.
• On August 28, 2025, Teva received FDA approval for generic liraglutide 3 mg referencing Saxenda — the FIRST generic GLP-1 RA for chronic weight management in the US. Hatch-Waxman ANDA pathway, AB-rated bioequivalent, pharmacist-substitutable subject to state pharmacy law.
• Saxenda's ~8% effect size is meaningfully smaller than Wegovy (~14.9%) and Zepbound (~20.9%) in cross-trial indirect comparison. Saxenda has been increasingly displaced on most commercial formularies for higher-effect weekly injections, but the daily liraglutide lane remains meaningful for patients blocked from Wegovy/Zepbound, patients hitting modest- target weight-loss goals, and patients preferring daily cadence.
• Aetna's 1227-C bulletin uses a unique 4% (NOT 5%) baseline-weight-loss continuation threshold for Saxenda — the most commonly-misread detail in third- party PA explainers. The 4% number traces to the §2 FDA-label stop rule.
• Boxed warning: thyroid C-cell tumors (class). Pregnancy: contraindicated; discontinue at least 2 months before planned pregnancy.

Related research

• When will each GLP-1 go generic? — the patent cliff timeline — for the Teva Saxenda-generic news in the context of the broader semaglutide and tirzepatide patent estates
• Aetna GLP-1 prior authorization guide — the verbatim Aetna 1227-C bulletin language including the 4% continuation rule
• Wegovy vs Mounjaro decision guide — the head-to-head comparison of the two highest-effect-size GLP-1 weight-management options that increasingly displace Saxenda
• Ozempic alternatives complete guide — framework for choosing between Saxenda, Wegovy, Zepbound, and Foundayo when Ozempic is unavailable or inappropriate
• Foundayo vs Wegovy vs Zepbound — head-to-head — the three FDA-approved weight-management GLP-1s that are the modern alternatives to Saxenda
• GLP-1 side-effect questions answered — the Q&A hub covering the GI, thyroid, pancreatitis, gallbladder, and discontinuation issues relevant to all GLP-1s including liraglutide
• Newest GLP-1 drugs (2026) — chronological coverage of recent GLP-1 approvals, including the Teva Saxenda generic